GlobalPost’s “Global Pulse” blog examines questions surrounding the use of the antiretroviral Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at high risk, as studies released and panel discussions held last week at the XIX International AIDS Conference (AIDS 2012) “raised concerns about the drug’s effect on the future of the AIDS fight.” According to the blog, “Leaders in the fight against AIDS are trying to work through these issues and figure out the best way to make use of Truvada as prevention.” The blog notes that the WHO last week “released a set of guidelines for how to use PrEP in demonstration projects” and quotes AVAC Director Mitchell Warren, AIDS Healthcare Foundation President Michael Weinstein, amfAR Vice President and Director of Public Policy Chris Collins, and Black AIDS Institute President and CEO Phill Wilson (Judem, 7/27).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.